neoadjuvant immunotherapy on the horizon in gastric cancers: 2022 esmo florida
Published 1 year ago • 41 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
0:30
emerging data on immunotherapies and tyrosine kinase inhibitors in lung cancer: 2022 esmo florida
-
2:54
minimally invasive approaches and enhancing surgical options for gastric cancer: 2022 esmo florida
-
1:34
potential for expanding the role of immunotherapies in colorectal cancers: 2022 esmo florida
-
0:54
expanding treatment choices and immunotherapy in non-melanoma skin cancers: 2022 esmo florida
-
7:00
expert report on neoadjuvant immune checkpoint inhibitors for nsclc
-
1:08
the role of neoadjuvant immunotherapy in msi-high gastric cancer
-
4:58
expert report on neoadjuvant immune checkpoint inhibitors for melanoma
-
0:57
neoadjuvant versus periop immunotherapy in nsclc | oncology brothers | #2023 #cancer #esmo
-
1:18
incorporating immunotherapy in cervical cancer and endometrial cancer treatment: 2022 esmo florida
-
2:48
changing course and improving dismal outcomes in lung cancer: 2022 esmo florida
-
2:46
#esmo22 highlights on neoadjuvant ici in locally advanced dmmr colon cancer: the niche-2 study
-
3:11
esmo 2020 highlights on pembrolizumab in la-hnscc: the gortec 2015-01 “pembrorad” study
-
0:29
adjuvant treatment for high risk hr breast cancer | esmo 2023 breast cancer highlights
-
2:22
#esmo22 highlights on neoadj. vs adjuvant pembrolizumab in resected stage iii-iv melanoma:swog s1801
-
1:14
gastric cancer updates at esmo 2022
-
1:09
novel targeted agents in lymphoma - “not our old chemotherapy drugs”: 2022 esmo florida
-
0:33
treating patients with breast cancer and a brca 1/2 mutation: 2022 esmo florida
-
0:31
biomarkers and risk assessment in oligometatstatic disease: 2022 esmo florida